Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]

Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]

Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]

Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]

Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]

Roustit M, Genty C, Lepelley M, Blaise S, Fromy B, Cracowski J-L, Bosson J-L. Amiloride treatment and increased risk of pressure ulcers in hospitalized patients. Br J Clin Pharmacol 2016;82:1685-7. [Ref.ID 101027]

Solomon DH, Liu C-C, Kuo I-H, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims . Ann Rheum Dis 2016;75:1674-9. [Ref.ID 100659]

Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016:22 de agosto. [Ref.ID 100584]

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. [Ref.ID 100151]

Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166-73. [Ref.ID 100079]

Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]

Anónimo. Riesgos de los fármacos anticolinérgicos en personas de edad avanzada. Butlletí Groc 2015;28:1-4. [Ref.ID 99838]

Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf 2015;38:1153-68. [Ref.ID 99783]

Park H, Satoh H, Miki A, Urushihara H, Sawada Y. Medications associated with falls in older people: systematic review of publications from a recent 5-year period. Eur J Clin Pharmacol 2015;71:1429-40. [Ref.ID 99782]

Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]

Jorgensen ME, Hlatky MA, Kober L, Sanders RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. ß-blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med 2015;175:1923-31. [Ref.ID 99749]